Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

R. G. Langley, K. Papp, A. B. Gottlieb, G. G. Krueger, K. B. Gordon, D. Williams, J. Valdes, C. Setze, B. Strober

Research output: Contribution to journal › Article › peer-review

59 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases